Studie AbbVIe M14-011 (Brightness)

AbbVIe M14-011 (Brightness)

A Randomized, Placebo-Controlled, Double-Blind Phase III Study Evaluating the Safety and Efficacy of the Addition of a PARP Inhibitor Plus Carboplatin Versus the Addition of Carboplatin in Combination with Standard Neoadjuvant Chemotherapy Versus Standard Neoadjuvant Chemotherapy in Subjects with Early Stage Triple Negative Breast Cancer (TNBC)

Frauenklinik Frauenklinik Ismaninger Str. 22 81675 München Germany

III

Rekrutierung beendet

Unbekannt / Unbekannt

1

Zielgerichtet - Therapieart: neoadjuvant